ASX: IPD

5 March 2015

**ASX ANNOUNCEMENT**

## World-Leading Cancer Centre joins L-Dex® trial

## HIGHLIGHTS

- The University of Texas MD Anderson Cancer Center has joined L-Dex post-approval clinical trial[1]
- Principal Investigator is, Sarah M. DeSnyder, MD, assistant professor, Surgical Oncology
- Joins Vanderbilt-Ingram Cancer Center and Macquarie Hospital as the third major research centre included in the trial

Brisbane, Australia – ImpediMed Limited (ASX: IPD) ("the Company") is pleased to announce that The University of Texas MD Anderson Cancer Center in Houston, Texas has joined the L-Dex international, post-approval clinical trial.

MD Anderson has been ranked by *US News and World Report* as one of the United States' top two cancer centres every year since the survey began in 1990. The institution is one of the nation's original three comprehensive cancer centres designated by the National Cancer Act of 1971 and is one of 68 National Cancer Institute (NCI) designated comprehensive cancer centres meeting the strict standards of scientific excellence and a multidisciplinary approach focused on cancer prevention, diagnosis and treatment.

Dr Sarah DeSnyder, who has been named principal investigator for this trial site, is a trained breast surgical oncologist. Her research efforts are focused on breast cancer, lymphoedema and body image issues after breast cancer treatment.

Dr DeSnyder commented, "I am pleased to participate in this important trial evaluating the significance of identifying subclinical lymphedema with the potential to improve lymphoedema care and our patients' quality of life."

"MD Anderson joins a list of prestigious sites involved in the post-approval clinical trial of the efficacy of L-Dex for improved patient outcomes. We are very pleased to have the support of leading clinicians such as Dr DeSnyder in this trial," said Richard Carreon, CEO of ImpediMed.

Details of the clinical trial can be found at the US National Institutes of Health website:
http://clinicaltrials.gov/ct2/show/NCT02167659?term=impedimed&rank=6

[1] Previous announcements at ASX on 30th October 2013, 26th June 2014 and 23rd July 2014

**Richard Carreon**
**CEO**

**ENDS**
**For further information contact:**

**Richard Carreon, ImpediMed CEO**
**Morten Vigeland, ImpediMed CFO**
**T: +1 (760) 585-2100**

**Kyahn Williamson, Buchan**
**Investor and Media Relations**
**T: +61 3 9866 4722**
**E: kwilliamson@buchanwe.com.au**

**About ImpediMed**
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au